The novelty of our study versus a multitude of former studies on BC DR is the assessment of expression profiles of specific DMEs, as well as CYP-mediated activities, in the resistance to two sub-therapeutic DOX concentrations. The gene discussed is PPIG; the disease is breast cancer.